Home > Healthcare > Medical Devices > Diagnostic Devices > Prostate Cancer Diagnostics Market

Prostate Cancer Diagnostics Market Share

Report ID: GMI6107
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Prostate Cancer Diagnostics Market Share

The market is characterized by the presence of several key players and a focus on technological innovation and strategic partnerships. In recent years, several market players have launched innovative products. For instance, Siemens Healthineers introduced advanced molecular diagnostic solutions that streamline the detection of prostate cancer. Other major players, such as Roche and Myriad Genetics, are expanding their product portfolios by integrating genomic testing to enhance prostate cancer detection capabilities.

Prostate Cancer Diagnostics Market Companies

Prominent players operating in the prostate cancer diagnostics industry include:

Abbott Laboratories
AdvaCare Pharma
Beckman Coulter, Inc. (Danaher Corporation)
Becton, Dickinson and Company
BIOMÉRIEUX
F. Hoffmann-La Roche Ltd.
FUJIFILM Holdings Corporation
GE Healthcare Technologies Inc.
Glycanostcs Ltd.
Healgen
KOELIS
Koninklijke Philips N.V.
Metamark Genetics, Inc.
miR Scientific
Myriad Genetics, Inc.
Proteomedix
Siemens Healthineers AG
Veracyte

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The industry was valued at USD 4.5 billion in 2023 and is expected to grow at a CAGR of 10.5% from 2024 to 2032, driven by the increasing prevalence of prostate cancer, heightened awareness of associated risk factors, ongoing technological advancements, and rising investments in innovative diagnostic modalities.

Diagnostic tests generated the highest revenue of USD 2.9 billion in 2023. They hold a significant share due to their critical role in early detection, with the PSA test being the most commonly used method to measure prostate-specific antigen levels in the blood, a key indicator of prostate cancer.

The North America market recorded USD 1.8 billion in 2023 revenue and is anticipated to grow at a CAGR of 9.9% between 2024 and 2032. The market's growth is fueled by high awareness levels, advanced healthcare infrastructure, an increasing aging population, and regular screening programs.

Key players include Abbott Laboratories, AdvaCare Pharma, Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), Becton, Dickinson and Company, BIOM